Home » Carbavance Earns Fast Track Status
Carbavance Earns Fast Track Status
The FDA has granted fast track status to The Medicines Company’s investigational antibiotic Carbavance to treat complex urinary tract infections.
The candidate is being developed to treat gram-negative infections, including those caused by carbapenem-resistant enterobacteriaceae.
Carbavance received qualified infectious disease designation in January 2014 for the treatment of cUTIs, intra-abdominal infections, HABP/VABP and febrile neutropenia.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May